Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing human pharma sales of EUR 20.8 billion (USD 22.1 billion), marking a 10.3% year-on-year (YOY) increase, excluding currency effects. Additionally, animal health sales rose by 6.9% YOY to EUR 4.7 billion (USD 4.9 billion), leading to combined group net sales of EUR 25.6 billion after a 9.7% YOY expansion. Notably, Boehringer Ingelheim’s pharma sales have surpassed those of Bayer AG, which reported EUR 18.08 billion in 2023 pharma sales, positioning Boehringer Ingelheim as Germany’s leading drug developer.
The human pharma business was bolstered by the strong performance of type 2 diabetes therapy Jardiance (empagliflozin) and idiopathic pulmonary fibrosis drug Ofev (nintedanib). Jardiance sales soared by 26.6% to EUR 7.38 billion (USD 7.83 billion), while Ofev sales grew by 8.8% to EUR 3.51 billion (USD 3.72 billion). Geographically, the Americas accounted for 48% of sales, Europe 32%, and Asia/Australia/Africa 20%.
Boehringer Ingelheim’s press release highlighted the company’s significant investments in R&D, which grew by 14.2% to EUR 5.8 billion, representing 22.5% of group net sales, with human pharma contributing EUR 5.2 billion of that amount. BI’s Chairman of the Board, Hubertus von Baumbach, commented, “I am excited to see how balanced and healthy our pipeline looks today.”
Key late-stage portfolio developments in 2023 included the oral MDM2-p53 antagonist brigimadlin, which entered a pivotal study for the rare cancer dedifferentiated liposarcoma. The development of oral HER2 inhibitor zongertinib was accelerated following robust early clinical data. Furthermore, the dual glucagon/GLP-1 receptor agonist survodutide achieved “groundbreaking Phase II results” in liver disease due to metabolic dysfunction-associated steatohepatitis (MASH) and advanced to Phase III for obesity. – Flcube.com
